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The increased use of medical implants has resulted in a concomitant rise in device-related infections. The majority of these infec-
tions are caused by Staphylococcus epidermidis biofilms. Immunoprophylaxis and immunotherapy targeting in vivo-expressed,
biofilm-associated, bacterial cell surface-exposed proteins are promising new approaches to prevent and treat biofilm-related
infections, respectively. Using an in silico procedure, we identified 64 proteins that are predicted to be S. epidermidis surface
exposed (Ses), of which 36 were annotated as (conserved) hypothetical. Of these 36 proteins, 5 proteins—3 LPXTGmotif-con-
taining proteins (SesL, SesB, and SesC) and 2 of the largest ABC transporters (SesK and SesM)—were selected for evaluation as
vaccine candidates. This choice was based on protein size, number of antigenic determinants, or the established role in S. epider-
midis biofilm formation of the protein family to which the candidate protein belongs. Anti-SesC antibodies exhibited the great-
est inhibitory effect on S. epidermidis biofilm formation in vitro and on colonization and infection in a mouse jugular vein cath-
eter infectionmodel that includes biofilms and organ infections. Active vaccination with a recombinant truncated SesC
inhibited S. epidermidis biofilm formation in a rat model of subcutaneous foreign body infection. Antibodies to SesC were
shown to be opsonic by an in vitro opsonophagocytosis assay. We conclude that SesC is a promising target for antibody medi-
ated strategies against S. epidermidis biofilm formation.
Staphylococcus epidermidis is considered to be themajor cause ofdevice-related infections, especially catheter-related infec-
tions. These infections have increased in number, owing to the
increased use of such devices (22). The ability to form biofilms on
medical implant surfaces is the main virulence factor of S. epider-
midis (25). Biofilms are notoriously resistant to both immune and
antimicrobial agents (7, 31). Currently, the only completely effec-
tivemethod for curing biofilm infections is to remove the infected
device, which is a risky, costly, and stressful procedure.
Different strategies are used against biofilm infections (20).
The traditional approach to prevent biofilm formation is admin-
istration of bactericidal agents to the patient or the biomaterial
(9). Other frequently utilized options involve the modification of
biomaterial surface to prevent initiation of bacterial colonization
(15, 16, 36, 40). However, these strategies have their disadvan-
tages. There is the ineffectiveness of traditional antibacterial com-
pounds due to the nature of biofilms and high prevalence of anti-
microbial resistance, there are the induction, generation, and
selection of resistance by the slow release of subinhibitory concen-
trations of antimicrobials from biomaterials, and there are the
problems linked to biochemical and chemical compatibility, in-
creased cost, short time effect, effect on mechanical properties,
and cytotoxicity (31, 41).
Immunoprophylaxis and immunotherapy targeting in vivo ex-
pressed biofilm-related proteins and cell surface components are
promising new approaches for the prevention and treatment of
biofilms. Most vaccines now available for human use are whole
(killed or attenuated) microorganisms or subunit vaccines. S. epi-
dermidis is a ubiquitous colonizer of human skin, and prior staph-
ylococcal infections do not cause immunological protection (37).
However, this does not imply that immunoprophylaxis and im-
munotherapy against S. epidermidis biofilms and infections would
not be possible.
Several recent studies have shown that antibodies against cell
surface components of S. epidermidis can affect the rate of biofilm
formation or adherence of these bacteria to medical devices in
vitro. Cerca et al. (5) showed that antibodies against polysaccha-
ride intercellular adhesion (PIA), which is identical to poly-N-
acetylglucosamine (PNAG), readily penetrated the S. epidermidis
biofilm and bound to the sessile cells. Sessile bacteria nevertheless
exhibited more resistance to opsonic killing than their planktonic
counterparts. Using polyclonal antibodies against a fibrinogen-
binding protein from S. epidermidis (Fbe), Pei et al. (23) could
block adherence of S. epidermidis to fibrogen-coated catheters in
vitro. Sun et al. (32) showed that monoclonal antibodies against
accumulation-associated protein (Aap) can significantly reduce
the accumulation but not initiation phase of S. epidermidis biofilm
formation in vitro. Maira-Litran et al. (19) showed that vaccina-
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tion of rats with purified PIA/PNAG can elicit protective immu-
nity against both CoNS and S. aureus. Hence, surface-expressed
components including S. epidermidis surface-exposed “Ses” pro-
teins (4, 12), PIA, and teichoic acids (13, 27) are potential targets
for vaccine development.
In the present study, we identified potential surface-exposed
proteins of S. epidermidis and investigated the potential use of
rabbit polyclonal antibodies raised against five “Ses” proteins and
against whole (killed)microorganisms for eradication of S. epider-
midis biofilms in vitro. For the most immunogenic protein, SesC,
we also tested the effect of immunization with recombinant anti-
gen (active immunization) on in vivo biofilm formation and in-
vestigated the immunological effector function of specific rabbit
polyclonal anti-SesC IgGs (SesC-IgGs). This was done by chal-
lenging animals in a newly developed central venous catheter mu-
rine model with S. epidermidis bacteria preincubated with SesC-
IgGs and by performing an in vitro opsonophagocytosis assay.
MATERIALS AND METHODS
In silico selection of Ses proteins. The complete sequence of S. epidermi-
dis ATCC 12228 (42) was retrieved from the National Centre of Biotech-
nology Information (NCBI) GenBank (http://www.ncbi.nlm.nih.gov
/GenBank/). N-terminal signal peptides and transmembrane domains in
S. epidermidis proteins were predicted with SignalP and TMHMM (http:
//www.cbs.dtu.dk/services/). Retention domain prediction lipobox mo-
tifs, peptidoglycan-binding domains, choline-binding domains, and
LPXTG motives were predicted using the PATTINPROT server (http:
//npsa-pbil.ibcp.fr/) (39). The prediction of protein subcellular localiza-
tion was reanalyzed using the online tool PSORTb v.2.0.4 (http://www
.psort.org/psortb/). The sequences of all identified Ses proteins were
subjected to antigenicity analysis using the “Predicting Antigenic Pep-
tides” server (http://imed.med.ucm.es/Tools/antigenic.pl).
Bacterial strains, plasmids, primers, and media. For biofilm inhibi-
tion studies, S. epidermidis strain 10b, which is a strong (PIA-dependent)
biofilm-forming strain (38) isolated from a patient with a proven cathe-
ter-related infection, was used. For recombinant protein production and
PCR screening of isolates, the sequences of the selected ses genes were
retrieved via the NCBI GenBank from the complete genome of the non-
biofilm-forming S. epidermidis strain ATCC 12228. On the basis of these
sequences, all primers were designed and purchased from Eurogentec
(Seraing, Belgium). Primers used in the present study are listed in Table 1.
Each ses genewas PCR-amplified using genomicDNA isolated from strain
10b as a template and sequenced. For recombinant protein production,
amplicons were cloned in pET11c (Stratagene, La Jolla, CA). The recom-
binant plasmids were transformed into Escherichia coli BL21(DE3). S.
epidermidis was grown in brain heart infusion broth (BHI; Oxoid) and E.
coli was grown in Luria-Bertani medium supplemented with 100 g of
ampicillin/mlwhen it was transformedwith plasmids. Solidmedium con-
sisted of the corresponding liquid medium supplemented with 1 to 2%
agar.
Bacterial isolates and species identification.A total of 76 S. epidermi-
dis clinical and commensal isolates from hospitalized patients (n  60),
the skin of healthy individuals (n  11), and five previously described
strains (strains 10b and 1457 [18], ATCC 35984/RP62A [12], and ATCC
12228 and TU3298 [1]) were collected. Clinical isolates were recovered
from blood cultures of neonates (n  45) with late-onset sepsis and an
intravascular catheter in place at the neonatal intensive care unit of the
ErasmusMC–SophiaChildren’sHospital inRotterdam,Netherlands, and
from different clinical specimens from patients (n  15) hospitalized at
University Hospital Gasthuisberg (Katholieke Universiteit Leuven) in
Leuven, Belgium. Species identification was performed with Vitek 2 (bio-
Mérieux).
PCR screening of ses genes in clinical and commensal isolates. We
performed a duplex PCR, amplifying both a ses gene and the 16S rRNA
gene. The primers used for PCR screening of ses genes were sesR1 and
sesF1 sets, and primers for the 16S rRNA gene were previously described
(35). For each strain, genomic DNA was extracted using a QIAamp DNA
minikit (Qiagen) with the addition of 30 g of lysostaphin/ml at the lysis
step.
Cloning, expression, and purification of histidine-tagged fusion
proteins. Recombinant extracellular domains of the Ses proteins were
expressed with hexahistidine tags at their N or C termini using the expres-
sion vector pET11c (Stratagene, La Jolla, CA). Each ses gene fragment was
PCR amplified using reverse and forward (sesF2 and sesR2 set) primers
incorporating flanking NheI and BamHI restriction sites and a sequence
TABLE 1 Primers used in this study
Primer Sequence (5=–3=)a Useb
sesCF1 GTTGATAACCGTCAACAAGG A
sesCR1 CATGTTGATCTTTTGAATCCC A
sesLF1 TGGGCCACTCAATACAGTCA A
sesLR1 TTGGCGTGTTTCTGTCTTTG A
sesMF1 CAGGTGCCTTGGAATCGC A
sesMR1 GCGTACCTTGCCAGTAGTC A
sesKF1 CCAATTACTAGTATTAAATTCAG A
sesKR1 CTACACTGTTAGACGTGAG A
sesBF1 GCTATGAAAAATAGTGGTGGC A
sesBR1 CGTAGTATGAATTGAGCTCAC A
sesCF2 ACGTGCTAGCGCAGATTCAGAAAGTACATC B
sesCR2 GAACAGCTACAGCTGATCATCACCATCACCATCACTAGGATCCGCAT B
sesLF2 CACGTGCTAGCCATCACCATCACCATCACAAAACGCAAGATGAAGCGAAA B
sesLR2 GGAACTCAAATTATTTATTAAGGATCCGCAT B
sesMF2 ACTGGCTAGCCATCACCATCACCATCACGGGGGCACCTCAAGTACAG B
sesMR2 GTTACACCAGAATCTATCTATTAGGATCCGCAT B
sesKF2 CACGTGCTAGCGCTGAATCAAACACTTCAGTTTCTTCT B
sesKR2 CTATTACCAAATACAGGTATGCATCACCATCACCATCACTAGGATCCGCAT B
sesBF2 ACGTGCTAGCGCAGCCGAAGTAACATCTC B
sesBR2 CTCAATTCATACTACGTAGGTCATCACCATCACCATCACTAGGATCCGCAT B
a Flanking restriction sites are underlined and in italics, and sequences coding for an N- or C-terminal His6 tag are indicated in boldface.
b A, used for PCR screening of ses genes in clinical and commensal isolates; B, used for cloning ses genes in pET11c.
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coding for a N or C-terminal His6 tag. Amplified products were cloned in
NheI- and BamHI-digested pET11c, and the resulting plasmids were
transformed into E. coli BL21(DE3). Pure plasmid DNA was isolated us-
ing a High Pure plasmid isolation kit (Roche Diagnostics), and PCR am-
plification and sequencing were used for verification. The recombinant
plasmids were used for recombinant protein production as previously
described in detail (28).
Preparationandpurificationofpolyclonal anti-rSes IgGantibodies.
Polyclonal antibodies were produced by Eurogentec by immunization of
rabbits with purified rSes proteins according to standard immunization
protocols. In addition, ethanol (80%)-killed S. epidermidis ATCC 12228
was used as whole-cell preparation to raise serum against the complete
surface of S. epidermidis. Briefly, specific-pathogen-free rabbits were im-
munized with 100g of rSes proteins or killed bacteria, and boosters were
given at 14, 28, and 56 days after the first immunization. Preimmune
serum was taken before the first immunization. After 87 days, the total
blood of the rabbit was collected, and the serum was stored at20°C.
Total IgGs from pre- and postimmune sera were purified by absorp-
tion to a protein G column (GE Healthcare) according to the manufac-
turer’s instructions. Only for SesC were specific rabbit polyclonal IgGs
(SesC-IgGs) further purified using antigen affinity purification, as pre-
viously described in detail (28). The purity and reactivity of the purified
IgGs against their respective recombinant proteins and ethanol killed cells
were determined by Coomassie blue staining of SDS-PAGE electrophore-
sis gels, enzyme-linked immunosorbent assay (ELISA), and Western blot
according to standard protocols. To evaluate the presence of the respec-
tive proteins on the surface of S. epidermidis, an indirect ELISA with the
pre- and postimmune sera on whole-cell and lysed S. epidermidis ATCC
12228was performed. To obtainwhole-cell S. epidermidis, the sediment of
an overnight culture was resuspended in 1ml of 0.9%NaCl and heated for
30 min at 56°C. For lysed cells, the sediment of an overnight culture was
resuspended in 1 ml of 0.9% NaCl with 100 g of lysostaphin (Sigma-
Aldrich)/ml. Subsequently, the suspension was incubated at 37°C for 4 h
in rotating tubes. For coating ELISA plates, the suspensions were diluted
to 107 CFU/ml in 0.9%NaCl. Hereafter, 100l of the dilutionwas applied
to each well on the plate, effectively coating each well with 106 CFU.
Coated plates were incubated overnight at 4°C before the test was per-
formed according to standard protocols (3). The test was considered pos-
itive when the optical density at 405 nm (OD405) of postimmune sera was
at least twice as high as the OD405 of preimmune sera after subtraction of
the average OD405 of the blank wells.
In vitro biofilm inhibition assays. Using a semiquantitative microti-
ter plate method (6, 32), the effect of pre- and postimmune IgGs against
rSes proteins on in vitro biofilm formation during the first 2 h (primary
attachment) and overnight (accumulation and establishment phase) was
studied. For quantification of biofilms, the following procedure was used.
A 20-l aliquot of frozen cultures of S. epidermidis strains 10b was inoc-
ulated into 5 ml of BHI and grown to the late-exponential/stationary-
growth phase in a shaking incubator at 37°C. Cultures were subsequently
diluted in BHI to an OD600 of 0.005 (5 10
6 CFU/ml) in fresh BHI.
To evaluate the effect of IgGs on the primary attachment of S. epider-
midis strain 10b, these starting cultures with an OD600 of 0.005 were
grown at 37°C to an OD600 of 1. Cultures were subsequently mixed with
either pre- or postimmune IgGs (10g/ml) and, after 2 h of incubation at
4°C, 200-l portions of the mixtures were pipetted into 96-well polysty-
rene microtiter plates (BD Biosciences, Heidelberg, Germany), followed
by incubation for 2 h at 37°C without shaking.
To study the effect of IgGs on overnight biofilm formation, the
cultures diluted to an OD600 of 0.005 were mixed with either pre- or
postimmune IgGs (10 g/ml) and, after 2 h of incubation at 4°C, 200
l of the mixtures (106 cell per well) was added to each well of 96-well
polystyrene microtiter plates, followed by incubation overnight at
37°C without shaking.
After the incubation, the plates were washed three times with phosphate-
buffered saline (PBS [pH 6.8], containing 0.5 M NaCl and 10 mM EDTA),
and adherent biofilms were stained with 200 l of 1% (wt/vol) crystal violet
(Sigma) for 10min, afterwhich theplateswerewashed three timeswithwater
anddried.Forquantification, 160l of 30%(vol/vol) acetic acidwasadded to
eachwell to dissolve the stain. TheOD595 of the dissolved stainwasmeasured
in a multipurpose UV/VIS plate reader. The percent inhibition of biofilm
formation was calculated by using the following formula: (A595, positive 
A595, antibody)/(A595, positive A595, negative) 100 (28, 32). The average inhi-
bition for each pre- or postimmune IgG was obtained from at least eight
independent measurements generated in at least two independent experi-
ments. S. epidermidis strain 10b in BHI without any added IgG was used as
positive control, and BHI without bacteria was used as a negative control.
Biofilm formation in immunized rats. For the vaccination experi-
ments, ex-germ-free Fisher (EGF) rats (n  6 per experiment) were di-
vided into two groups of three rats each. Each rat in the first group was
immunized twice intraperitoneally with first 100g of rSesC (dissolved in
normal saline) in complete Freund adjuvant (CFA) and 2 weeks later a
second time with 50 g of rSesC (dissolved in normal saline) in incom-
plete Freund adjuvant (IFA). The second group of rats was injected with
the same volume of normal saline in CFA and IFA but without antigen.
Two weeks after the second immunization, the immune response of pre-
and postimmunization sera of all rats was tested by ELISA. Subsequently,
five catheter (Arrow International, Reading, PA) fragments preincubated
with S. epidermidis 10b bacteria (104 cells/catheter) were implanted in
each rat and 24 h later explanted as previously described (28), and the
numbers of sessile cells were quantified by CFU counting as previously
described (24). Briefly, after gentle cleaning with 0.9%NaCl, the catheters
were placed in a tube containing 1 ml of 0.9% NaCl. Tubes were vortex
mixed for 10 s, sonicated for 10 min at 40 kHz in a water bath (Branson
2200; Branson Ultrasonics), and vortex mixed again for 10 s. Thereafter,
tube contents were diluted and 50-l aliquots of 10-fold dilutions were
plated on tryptone soy agar (TSA; Oxoid) plates, using a spiral plating
system, and the plates were incubated at 37°C overnight. Colonies on all
plates were counted, and the number of bacteria was defined as the mean
of at least five quantitative cultures. All animal experiments were repeated
at least twice and conducted in compliance with the guidelines for animal
experimentation. All experimental protocols were approved by the Insti-
tutional Animal Care Commission and Ethical Committee of the KU
Leuven.
Biofilm formation in jugular vein-catheterized (JVC)mousemodel.
In order to investigate the effector function of SesC-IgGs, we developed
and used a previously described central venous catheter murine model
(17, 21) that reflects the clinical situation of catheter colonization by
contaminated infusions. Briefly, 4-weeks-old Swiss-Webster mice from
Taconic (n 9mice per experiment, with the experiment repeated twice)
were divided into three groups of threemice each.Mice were anesthetized
with sodiumpentobarbital (nembutal, 40 to 60mg/kg [bodywt]) injected
intraperitoneally. The animal was then placed in dorsal recumbency un-
der a dissecting microscope. A small vertical incision was made using a
scalpel, and the right jugular vein was identified, mobilized, and exposed
with blunt surgical dissection. A single lumen polyethylene catheter (in-
ternal diameter, 28 mm; outer diameter, 61 mm; length, 6 cm; insertion
length, 1 cm; Intramedic [Becton Dickinson, catalog no. 427400]) was
inserted into the right jugular vein and advanced into the superior vena
cava via a small incision in the veinmade with vein scissors. A ligature was
then tied loosely around the catheter, and patency was verified. Once
blood flow had been established, the catheter was anchored in place and
flushed with 10 l of saline. Subsequently, a small midline skin incision
was made between the scapulae. The catheter port was tunneled back
through the scapular incision. The incisions were then closed with
stitches. Mice were housed separately and monitored for recovery. An
overnight culture of S. epidermidis strain 10b, grown to the late exponen-
tial/stationary growth phase in BHI, was pelleted, resuspended, and di-
luted to an OD600 of 0.3 (3E08) in 0.9%NaCl. Three inoculums were
taken, one without any IgG, while two others were mixed with either
preimmune orSesC-IgGs (80g/ml) and incubated for 2 h at 4°C. After
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a 24-h recovery from surgery, 150 l (5E07) of the mixture was in-
jected through the catheter lumen. Animals in the first, second, and third
groups received bacteria, bacteria preincubated with preimmune IgGs,
and bacteria preincubated with SesC-IgGs, respectively. After the blood
samples were obtained at day 5 postinfection, the animals were sacrificed.
The catheters were aseptically removed, and the portion (1 cm) that was
inside the vein was cut, gently washed, and processed for quantitative
culturing as explained above. To compare the overall infection rate, the
spleens, livers, hearts, veins, and right kidneys were aseptically harvested,
mechanically homogenized in 0.9% NaCl, and processed for quantitative
cultures as explained above.
Opsonophagocytosis of planktonic and biofilm bacteria by SesC-
IgGs. To prepare the bacteria for the evaluation of susceptibility to op-
sonic killing, the overnight culture of S. epidermidis 10b in BHI was pel-
leted for 5 min at 12,000  g at 4°C, washed twice with PBS, and
subsequently diluted to an OD600 of 1. For evaluation of opsonophagocy-
tosis of planktonic cells, 10 l of bacterial suspension was used, and for
evaluation of opsonophagocytosis of biofilm cells, 5-mm catheter (Arrow
International) fragments were added to the bacterial suspension, incu-
bated at 37°C for 2 h, and subsequently washed with 1 ml of PBS. The
opsonophagocytosis assay was performed with fresh blood obtained from
human healthy volunteers as previously described (29), with some mod-
ifications. Briefly, fresh whole blood from two volunteers was collected in
vacuum blood collection tubes containing the anticoagulant heparin and
then aliquoted into 1.5-ml microcentrifuge tubes (0.5 ml/tube). Catheter
fragments preincubated with S. epidermidis strain 10b or planktonic bac-
teria (10 l of bacterial suspension with an OD600 of 1) after 1 h preincu-
bation at 4°C with preimmune or SesC-IgGs (30 g/ml) or the same
volume of PBS or nothingwere added to the 1.5-mlmicrocentrifuge tubes
containing 0.5 ml of fresh blood. Tubes were incubated at room temper-
ature with gentle rocking and, after 30min, the samples containing plank-
tonic bacteria were serially diluted and plated onto TSA plates to deter-
mine the number of surviving CFU. For samples containing catheter
fragments, catheter fragments were first removed and gently washed with
1 ml of saline and then processed for quantification of the number of
surviving cells on the catheter fragments as explained above. In order to
determine the input CFU in samples containing planktonic or sessile bac-
teria attached to the catheter fragments, a portion the of untreated plank-
tonic samples was serially diluted and plated onto TSA plates, or the num-
ber of bacteria attached to the untreated catheter fragmentswas quantified
as explained above. All samples were assayed in triplicate, and all experi-
ments were repeated at least twice.
Statistical analysis. In the present study, for all of the in vitro and in
vivo experiments, data were pooled from two independent experiments.
For all data from the bacterial adherence and opsonophagocytosis assays,
two hypotheses were tested. A significant change in the adherence levels or
survival rates for different IgGs (preimmune or anti-Ses IgGs) was tested
with a one-way analysis of variance (ANOVA). A significant difference in
adherence for an experiment set including pre- and postimmune IgGs
from a particular rabbit was tested with a two-way ANOVA. When the
one-way ANOVA was significant, two-sided univariate tests with a cor-
rection for multiple comparisons were performed (Bonferroni test) to
locate the significant differences.
For in vivo experiments, differences between the control and vaccine
groups or between groups injected with bacteria treated with preimmune
or SesC-IgGs were examined between the number of bacteria recovered
from the catheter fragments (in both in vivo models) or from the organs
(only JVC model) using one-way ANOVA. A P value of 0.05 was con-
sidered significant.
RESULTS
Selection of Ses proteins. In order to identify the potential Ses
proteins we used our in silico selection procedure summarized in
the diagram shown in Fig. 1. In total, from the 2,419 predicted S.
epidermidis proteins, 64 proteins were identified as Ses proteins.
Of these, 36 were (conserved) proteins with a hypothetical func-
tion (see Table S1 in the supplemental material). LPXTG motif-
containing and ABC transporter lipoproteins are two major types
of cell surface proteins thatmay play important roles in the patho-
genesis of S. epidermidis infections (11, 26). We selected three
predicted LPXTG motif-containing proteins and two predicted
lipobox-containing ABC transporter proteins of which the func-
tion had not yet been characterized. These were based on the pro-
tein size, the number of antigenic determinants and the impor-
tance of the protein family, to which the candidate protein
belongs, in S. epidermidis biofilm formation and pathogenesis
(Table 2).
Presence of ses genes in S. epidermidis isolates.We hypothe-
sized that the ideal targets for immunoprophylaxis or immuno-
therapy against S. epidermidis biofilms would be surface compo-
nents that were conserved across the species, in particular those
which are highly expressed in the bloodstream and in biofilms,
with a possible role in biofilm formation or an essential function.
To verify the conserved nature of the selected genes, we investi-
gated the distribution of ses genes in clinical and commensal iso-
lates of S. epidermidis.
Gene-specific PCR amplification of sesM, sesB, and sesC was
FIG 1 In silico selection of genes coding for “surface-exposed proteins” of S. epidermidis. SP, signal peptide; TM, transmembrane helix; PBD, peptidoglycan-
binding domain; CBD, choline-binding domains.
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positive in all tested S. epidermidis isolates (n  76); for sesL this
was 68% (n 52 of 76 isolates), and for sesK this was 9% (n 7 of
76 isolates). There was no significant difference in the prevalence
of the sesL and sesK genes in clinical or commensal isolates. We
also studied the in vitro and in vivo expression of five selected ses
genes in planktonic and sessile bacteria, as previously explained
(28). Gene expression studies showed that the selected ses genes
are expressed at the level of the transcriptome in both planktonic
and sessile bacteria in vitro and in vivo. However, the in vitro and in
vivo expression patterns of ses genes in planktonic andbiofilmcells
varied widely (data not shown).
Recognition of Ses proteins by polyclonal antibodies. The
purity and reactivity of the purified IgGs against their respective
recombinant proteins and ethanol-killed cells were determined by
Coomassie blue staining of SDS-PAGE gels, ELISA, and Western
blotting according to standard protocols. Figure 2 shows examples
of such evaluations. To evaluate the recognition of selected Ses
proteins by the antisera and their expression on the surface, we
performed Western blots and ELISAs on purified recombinant
proteins and S. epidermidis ATCC 12228 lysate for each anti-Ses
serum (Table 3). For antiserum against SesC, SesL, and SesB, both
Western blotting and ELISA were positive against the respective
recombinant protein and bacterial lysate. ELISA against whole-
cell S. epidermidisATCC12228was also positive for these antisera,
as was whole-cell antiserum against these three recombinant pro-
teins. For antiserum against SesM, Western blotting and ELISA
against SesM recombinant protein and S. epidermidis lysate were
positive, but ELISA against whole-cell S. epidermidiswas negative.
The latter was also true for antiserum against SesK, but addition-
ally, Western blot results against whole-cell S. epidermidis for this
antiserum and whole-cell antiserum against rSesK were negative
as well. These data suggest that the selected proteins are surface
exposed except possibly for SesK and SesM, which are not ex-
pressed under the chosen culture conditions for S. epidermidis.
Biofilm inhibition by purified polyclonal anti-rSes-IgGs in
vitro. Of the five antibodies, the maximum inhibition of initial
attachment and overnight biofilm formation of the bacteria on
polystyrene surfaces (Fig. 3A and B), observed in these in vitro
experiments, occurred when bacteria were preincubated with
IgGs purified from the serumof the rabbit immunizedwith rSesC.
This reduction for overnight biofilm formation was however not
statistically significant (P 0.01 and P	 0.05, one- and two-way
ANOVAs).
Effect of immunization with rSesC on biofilm formation. In
order to test the potential of SesC as a target for vaccination
against S. epidermidis biofilms, rats were actively immunized with
rSesC. The number of sessile bacteria attached to the catheter frag-
ments 24 h after implantation in the group immunizedwith rSesC
TABLE 2 Ses proteins selected by in silico procedure and used in this study
Locus Putative product
Protein
accession no.
Protein size (no.
of amino acids) Motif
No. of antigenic
determinants
SE2232 Conserved hypothetical protein (SesC) NP_765787.1 676 LPXTG 20
SE1106 ABC transporter membrane-spanning protein (SesL) NP_764661.1 564 Lipobox 16
SE1981 Nickel ABC transporter/nickel-binding protein (SesM) NP_765536.1 491 Lipobox 18
SE1501 Hypothetical protein (SesK) NP_765056.1 415 LPXTG 11
SE2152 Hypothetical protein (SesB) NP_765707.1 196 LPXTG 7
FIG 2 (A) Coomassie-stained SDS-PAGE gel (12%) of rSes. Lane 1, SDS-PAGE marker; lane 2, total E. coli extract after induction of SesC expression and cell
lysis; lane 3, protein extract after binding the His-tagged SesC to the nickel column; lane 4, protein extract after washing the nickel column; lane 5, SesC
recombinant protein after elution; lane 6, negative control. (B) Affinity of preimmune () andSesC-IgGs () to rSesC. An indirect ELISAwas performed using
a 96-well ELISA plate coated with rSesC. IgGs were added to each well and incubated for 3 h at 37°C. Bound IgGs were measured at OD405 with an alkaline
phosphatase-conjugated anti-rabbit immunoglobulin. x and y axes indicate the log10 IgG concentration (ng/ml) and the OD405 absorbance, respectively.
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compared to the normal saline-immunized group was signifi-
cantly reduced (20-fold; P 0.01; one-way ANOVA) (Fig. 4).
Effect ofSesC-IgGs on the overall infection rate in the JVC
mouse model. To investigate the effector function of SesC-IgG
antibodies in vivo, the mean numbers of bacteria recovered from
the blood, catheters, veins, livers, spleens, hearts, and kidneys of
animals in different groups were compared. Preincubation of bac-
teria with SesC-IgGs could significantly reduce the number of
bacteria recovered from the catheter, vein, spleen, heart, liver, and
kidney by 26-, 71.5-, 331-, 327-, 215-, and 52-fold, respectively
(P 0.01, one-way ANOVA), whereas preincubation of bacteria
with preimmune IgGs had no effect on the infection rates (Fig. 5).
Almost no bacteria were found in the circulation.
SesC-IgGs are opsonic andmediate opsonophagocytosis of
planktonic and biofilm cells. Incubation of bacteria in the plank-
tonic or sessile state with whole blood for 30 min led to a signifi-
cant reduction (	1 log10) in PBS-treated versus input bacteria
(P 0.001) (Fig. 6). Preincubation of bacteria in both planktonic
and sessile forms with SesC-IgGs significantly enhanced the op-
sonophagocytic killing of bacteria (P 0.001, one-way ANOVA)
compared to bacteria treated with preimmune IgGs or PBS (Fig.
6). There was no difference between bacteria treated with preim-
mune IgGs and PBS. SesC-IgGs showed the same level of en-
hancement of opsonophagocytic killing of bacteria for both
planktonic and sessile bacteria.
DISCUSSION
In this studywe tried to identify new potential target(s) for immu-
noprophylaxis and immunotherapy against S. epidermidis biofilm
formation. Using our in silico selectionmethod, we first identified
potential Ses proteins. Nine of these proteins were proteins with
an LPXTG motif (4, 12). Five LPXTG motif-containing proteins
(Aap, Bhp, SdrF, SdrG, and SesI) are known to play important
roles in the pathogenesis of S. epidermidis infections (2, 8, 10, 14,
30). In publicly available genomes of S. epidermidis strains RP62A
and ATCC 12228, respectively, 11 and 10 genes encoding LPXTG
motif-containing proteins have been identified (4), including
TABLE 3 Western blot and ELISA data obtained using immune sera
against recombinant Ses proteins and whole-cell S. epidermidis ATCC
12228a
Antiserum
target
On respective
rSes protein
On
S. epidermidis
lysate
On WC
S. epidermidis
(ELISA)WB ELISA WB ELISA
SesC     
SesL     
SesM     –
SesK   –  –
SesB     
WC *    
a WB, Western blot; WC, whole cell. *, Western blot with whole-cell antiserum on
recombinant proteins was positive for all proteins except SesK.
FIG 3 Effect of total IgGs purified from preimmune () and anti-Ses (L, K, M, B, and C) and anti-whole-cell (WC) sera () on primary attachment (A) and
overnight biofilm formation (B) of S. epidermidis strain 10b on a polystyrene surface. Overnight cultures were diluted, mixed with IgGs, incubated for 2 h at 4°C,
and then transferred into the wells. After 2 h (A) or 14 h (B) of incubation at 37°C, the plates were washed and stained with crystal violet, and the OD595 was
measured. The error bars indicate the standard deviations. The data are the averages of eight measurements in two independent experiments. Biofilm inhibition
was as defined in the text.
FIG 4 Effect of immunization of EGF rats with rSesC on S. epidermidis 10b
biofilm formation. Rats (n  6) were divided into two groups of three rats
each. Rats in the vaccine group were immunized twice intraperitoneally with
rSesC. Rats in the control groupwere injected with the same volume of normal
saline. At 2 weeks after the second immunization, the immune response was
tested by ELISA. Subsequently, catheter fragments preincubated with S. epi-
dermidis strain 10b (104 cells/catheter) were implanted in rats and 24 h later
explanted, and the numbers of adherent bacteria on the catheters were quan-
tified. The experiment was repeated twice. Data for each group were obtained
from adherent bacteria to 30 catheter fragments implanted in six rats (five
catheters per animal, three rats per group in each experiment, two groups, two
independent experiments). The error bars indicate the standard errors of the
mean.
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those already mentioned. Except for the five LPXTG motif-con-
taining proteinsmentioned above, the role of other LPXTGmotif-
containing proteins has not been studied yet. The second major
type of cell surface proteins in Gram-positive bacteria are lipopro-
teins that participate in a wide range of cell envelope functions
(33). Themajor functional category of lipoproteins are the solute-
binding proteins of ABC transport systems for the import of a
diverse range of substrates (34). Due to the importance of these
two families of proteins, five proteins with unknown function, i.e.,
three hypothetical LPXTGmotif-containing proteins (SesC, SesK,
and SesB) and two ABC transporters (SesL and SesM), were se-
lected for further studies. This selection was also based on the
protein size and the number of antigenic determinants.
We showed byWestern blotting that the recombinant proteins
of the selected proteins except for SesKwere recognized by whole-
cell antisera, suggesting these proteins, except possibly for SesK,
are most likely surface exposed. Anti-SesK and anti-SesM antisera
did not recognize whole cells, suggesting that SesK and SesM are
not (sufficiently) expressed under the culture conditions chosen.
In addition, sesK is in only present in10% of tested isolates.
Total IgGs isolated from the hyperimmune sera of rabbits im-
munized with rSesC showed the highest inhibition effect on pri-
mary attachment and biofilm formation in vitro, indicating a pos-
sible role for this protein in S. epidermidis biofilm formation. The
lower effect of IgGs isolated from the sera of animals immunized
with other Ses proteins or whole cells can be due to either a low
expression level of selected Ses proteins on the surface during
biofilm formation or to the fact that the concentration of antibod-
ies used was too low. Also, some of the selected proteins may not
be accessible to antibodies in the biofilm structure.
Based on the in vitro biofilm inhibition studies, SesC seemed to
be the most promising target for prevention and treatment of S.
epidermidis biofilms. We therefore selected SesC for further stud-
FIG 5 Effect of preincubation of S epidermidis strain 10b with preimmune or SesC-IgGs on the overall infection rates in the JVCmouse model. A single lumen
polyethylene catheter was surgically inserted into the right jugular vein of Swiss-Webster mice. After 24 h, an overnight culture of S. epidermidis strain 10b
(3E08) in 0.9%NaCl was mixed with preimmune or SesC-IgGs (80 g/ml) or the same volume of PBS, followed by incubation for 2 h at 4°C. After a 24-h
recovery from surgery, 150l (5E07) of the mixture was injected through the catheter lumen. After 5 days, the overall infection rates in different organs and
the catheter colonizationwere quantified. Data for each groupwere obtained frombacteria recovered from the catheter or organs of six infectedmice (threemice
per group in each experiment, three groups, two independent experiments). The error bars indicate the standard errors of the mean.
FIG 6 Effect of preincubation of S epidermidis strain 10b with SesC-IgGs on
phagocytosis of planktonic () and sessile () bacteria by humanneutrophils.
Bacteria grown in planktonic form or attached to catheter fragments were
tested for their ability to survive in human blood after preincubation with
preimmune IgGs or SesC-IgGs. Surviving bacteria were measured by viable
counting. The data are presented as themean log10 of surviving CFU. The data
for each group are the average of six measurements in two independent exper-
iments. The error bars represent the standard deviation of the measurements.
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ies. Unfortunately, attempts to create sesC knockoutmutants have
been unsuccessful, and natural S. epidermidis sesC mutants have
not been found yet. However, there are indications that SesC
might be a potential fibrinogen-binding protein, playing a role in
the attachment to abiotic surfaces (28). Further studies on the
function of SesC in biofilm formation are therefore warranted.
Our in vivo rat model, although closely resembling the subcu-
taneous models for catheter-related infections and mimicking in-
traoperative contamination with skin flora, does not mimic con-
ditions found in the human intravascular system. Intravascular
devices are nevertheless themost frequently usedmedical devices.
In addition, the immune response at the site of infection in our
subcutaneous rat model may not reflect the immune response to
the intravascular device-related infections in peripheral blood.
Hence, we developed and used our JVC model to investigate the
immune response and effector function of antibodies.
The primary functions of antibodies are neutralization and
opsonization. The effect of SesC-IgGs on S. epidermidis bio-
films in vitro, in the absence of immune system components,
suggested a neutralizing effect of SesC-IgGs or blocking of the
function of SesC. However, in vivo, in addition to neutraliza-
tion, antibodies can opsonize their ligand, thus facilitating its
uptake and destruction by natural killer cells, activating com-
plement, and enhancing phagocytosis. The effect of SesC-IgG
antibodies on opsonophagocytosis of planktonic cells in vitro
indicates their potential opsonic activity, whereas the reduc-
tion of the number of sessile bacteria on catheters in this ex-
periment can be due to both neutralization and the opsonic
activity of SesC-IgG. It is possible that binding by SesC-IgG
of SesC on the surface of sessile bacteria triggers their detach-
ment from catheter fragments and subsequent phagocytosis by
neutrophils.
The 20-fold reduction of attached bacteria in the vaccinated
group compared to the control group suggests a significant ex-
pression of SesC in sessile bacteria and is consistent with a role of
this protein in S. epidermidis biofilm formation. This is also in line
with our in vitro data and a previous report that subcutaneous
injection of anti-SesC-IgGs at the place of implantation of catheter
fragments reduced the number of attached bacteria to the catheter
fragments 60-fold compared to the control group treated with
preimmune IgGs (28). The JVC mouse model is a more physio-
logical model for investigating the mechanism of action of anti-
bodies on S. epidermidis biofilms and organ infections, since the
reduction in the overall infection rate in JVCmurinemodel can be
due to both neutralization and the opsonization activity ofSesC-
IgG antibodies. The clear effect of the SesC-IgG antibodies on
the organ infections suggest, on the one hand, a significant role of
sesC in tissue infections and, on the other hand, confirm the hy-
pothesis thatSesC-IgG antibodies work in preventing the adher-
ence of the bacteria.
In conclusion, antibodies against recombinant SesC were
shown to be both neutralizing and opsonic to S. epidermidis and
can inhibit biofilm formation in vitro and in vivo. Active vaccina-
tion with SesC and preincubation of bacteria with SesC-IgGs
showed a reduction of biofilm formation and infection rates in
vivo. The findings of the present study are consistent with those of
Shahrooei et al. (28), who reported that SesC might play an im-
portant role in S. epidermidis biofilms and be a promising target
for immunoprophylaxis and immunotherapy of S. epidermidis
biofilms. The precise role of SesC in S. epidermidis biofilm forma-
tion remains to be identified.
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